NEW YORK (GenomeWeb News) – Biotech firm Odyssey Thera has raised $2.8 million and initiated a research service contract with Merck, it announced on Thursday.

The financing, consisting of new funds and debt conversion, will go toward the development and expanded commercialization of the San Ramon, Calif.-based company's technologies and products.

Participants in the round include Merck, HBM Partners, Burrill & Co., and Lonza.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.